Medline stock begins trading today on Nasdaq at the $29 IPO price, marking the biggest public market debut of 2025. The medical supplies giant raised $6.26 billion in Wednesday night’s upsized offering, cementing its position as the year’s largest IPO globally. Trading under the ticker MDLN, the Illinois-based company gives investors their first chance to own a piece of healthcare’s essential supply chain.
🔥 Quick Facts
- $6.26 billion raised in upsized IPO with 216 million shares at $29 each
- $54.5 billion market valuation at pricing, making Medline worth more than major competitors
- 2025’s biggest IPO globally, breaking the previous year’s records for healthcare deals
- 43,000 employees operate across multiple continents with $25.5 billion in 2024 revenue
How Medline Became Healthcare’s Invisible Giant
Intuit emerges as best software stock for 2026 while stock crashes to bargain levels analysts didn’t expect
2026 tax brackets shock Americans with hidden paycheck truth nobody expected
For nearly 60 years, Medline Industries has quietly dominated the medical supplies distribution space without the household name recognition of competitors. Founded in 1966 and headquartered in Northfield, Illinois, the company supplies hospitals, nursing homes, clinics, and healthcare providers with over 335,000 products ranging from surgical gloves to hospital beds.
The company’s growth trajectory proved undeniable—18% compounded annual growth over five decades attracted major private equity attention. In June 2021, a consortium of Blackstone, Carlyle Group, and Hellman & Friedman acquired Medline for approximately $34 billion in one of healthcare’s largest leveraged buyouts. The Mills family, who founded and controlled Medline, retained their largest shareholder position worth an estimated $6 billion to $7 billion based on this IPO valuation.
Marcus Lemonis takes CEO role at Bed Bath & Beyond with $25M cost-cutting plan and watch what industry experts are saying about his next move
SPX surges 34 points at open with shocking tech recovery, here’s what caused the unexpected Venezuela rally
Today’s market debut represents a critical milestone for private equity’s healthcare playbook—proving that even mature, stable businesses can deliver blockbuster returns to public market investors when growth fundamentals remain solid.
The IPO Numbers That Shocked Wall Street
Medline’s pricing success tells a story of overwhelming investor demand. The company initially planned a 179 million share offering at $26 to $30 per share, targeting roughly $5.4 billion. But Tuesday night, bankers upsized the deal by roughly 20%, selling 216 million shares at the top of the range—$29—demonstrating institutional appetite for large-cap healthcare bets.
That $6.26 billion haul now ranks as the largest IPO since Rivian’s 2021 debut and surpasses every other 2025 global listing. The pricing implies a post-money valuation above $50 billion, positioning Medline as a mega-cap, blue-chip player worthy of passive indexing strategies and institutional mandates.
| Metric | Details |
| Shares Offered | 216 million shares at $29.00 per share |
| Gross Proceeds | $6.26 billion (largest 2025 IPO) |
| Market Cap at IPO | $54.5 billion |
| Trading Symbol | MDLN on Nasdaq Global Select Market |
| 2024 Revenue | $25.5 billion (up from $23.23 billion in 2023) |
Why Hospitals and Healthcare Systems Trust Medline
Medline’s business model rests on an unglamorous truth—healthcare providers need reliable supply chains more than flashy innovation. The company operates a vast distribution network delivering 95% of orders within one day to U.S. customers, a logistical edge that locks in long-term contracts and customer switching costs.
The product portfolio spans 335,000-plus SKUs across critical categories: advanced wound care, surgical instruments, infection prevention products, durable medical equipment, and diagnostic supplies. This breadth means hospitals consolidate vendors, reducing procurement complexity. When reimbursement pressures squeeze hospital margins, buyers gravitate toward trusted suppliers offering volume discounts and operational efficiency gains.
“Medline has posted consistent growth since its 2021 leveraged buyout, with the company reporting $25.5 billion in net sales for 2024, up from $23.23 billion in 2023 and $21.45 billion in 2022 — a 20% topline gain over two years.”
— Distribution Strategy Analysis, Q4 2025
The company’s strategic focus shifted post-acquisition—branded products now carry higher margins than commodity items, and the January 2024 acquisition of United MedCo expanded Medline’s foray into health plans and managed care. This vertical integration trend diversifies revenue beyond traditional distribution, opening new growth avenues.
What Medline’s IPO Means for Healthcare Investors
This debut signals renewed confidence in healthcare infrastructure plays and essential services businesses. Unlike biotech or medical device innovators dependent on pipeline breakthroughs, Medline’s model derives strength from sticky customer relationships and operational excellence. The company’s ability to grow 18% annually for five decades—through recessions, pandemics, and regulatory shifts—demonstrates defensive characteristics attractive to risk-averse institutional money.
Medline also represents a rare arbitrage victory for private equity in healthcare. Blackstone, Carlyle, and Hellman & Friedman will achieve massive returns on their 2021 investment, validating the consortium’s thesis that consolidating and optimizing an already-dominant medical supplies business could fund outsized exits. The public market’s willingness to price this deal at a premium $54.5 billion valuation suggests investors see sustainable advantages and pricing power ahead.
What Happens Next for Medline Share Price and Business?
The real test starts now. Trading in secondary markets often produces volatility as bankers, insiders, and speculators rebalance positions. First-day pops followed by corrections remain common in mega-cap IPOs. Investors should monitor early trading data and forward guidance closely—management commentary on 2026 growth expectations and capital allocation plans will drive sustained demand.
Medline faces competitive pressures from McKesson Corporation, Cardinal Health, and Owens & Minor, all offering overlapping distribution capabilities. However, Medline’s sheer scale, brand loyalty among healthcare systems, and operational advantages provide defensibility. Margin expansion and international growth remain key catalysts. The company’s success in foreign markets—particularly in emerging economies where healthcare infrastructure spending accelerates—could reshape valuation multiples higher if execution proves flawless.
Sources
- Reuters – Medline IPO coverage and deal terms
- Bloomberg – Market valuation and investment analysis
- Wall Street Journal – IPO pricing and market response
Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.